**Appendix Table1. Clinical properties of the ovarian cancer patients used in the analysis.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dataset | No. of tumor samples involved | No. ofnormalsamplesinvolved | Death event | Median overall survival(Mon) | Serous/Endometrioid/Clear cell/Mucinous/Others | Grade(1/2/3) | Stage(1/2/3/4) | Debulking(Optimal/Suboptimal) | Primary therapy outcome(Complete Remission/ Partial Remission/ Progressive Disease/ Stable Disease) | Age | History of neoadjuvanttreatment(Yes/No) | Initial pathologic Diagnosis method(Tumor resection/Cytology/Other) |
| TCGA | 376 | 0 | 235 | 17.267 | 376/0/0/0/0 | 2/49/314 | 4/24/294/49 | 256/72 | 205/44/29/24 | 34~87 | 1/374 | 310/41/25 |
| GTEX | 0 | 88(ovarysamples) | NA | NA | NA | NA | NA | NA | NA | 20~60 | NA | NA |
| GSE26712 | 28 | 185 | 129 | 38.28 | NA | High① | Late② | 90/95 | NA | NA | NA | NA |
| GSE63885 | 101 | 0 | 66 | 36.83 | 72/12/9/0/7 | 0/10/51 | 0/2/64/11 | 15/60 | NA | NA | NA | NA |

①No specific grade shown.

②No specific stage shown

NA, data not available; /out of, total number of patients with available clinical data